BioLife Solutions, Inc. (NASDAQ:BLFS) Receives Consensus Rating of “Hold” from Analysts

Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) have been given an average rating of “Hold” by the five research firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $32.00.

Several brokerages have recently weighed in on BLFS. Zacks Research cut BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a research note on Monday, April 20th.

Insider Transactions at BioLife Solutions

In other BioLife Solutions news, major shareholder Casdin Partners Master Fund, L sold 650,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $23.70, for a total transaction of $15,405,000.00. Following the completion of the transaction, the insider owned 4,757,165 shares in the company, valued at approximately $112,744,810.50. This trade represents a 12.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders have sold 1,200,000 shares of company stock worth $28,125,000. 2.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On BioLife Solutions

A number of hedge funds have recently bought and sold shares of BLFS. Global Retirement Partners LLC acquired a new stake in BioLife Solutions during the 4th quarter worth about $30,000. Kemnay Advisory Services Inc. acquired a new position in shares of BioLife Solutions in the 4th quarter valued at about $35,000. Quarry LP lifted its stake in shares of BioLife Solutions by 50.9% in the 3rd quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock valued at $54,000 after purchasing an additional 713 shares during the period. Hantz Financial Services Inc. boosted its position in shares of BioLife Solutions by 42.4% during the 4th quarter. Hantz Financial Services Inc. now owns 2,673 shares of the medical equipment provider’s stock valued at $65,000 after purchasing an additional 796 shares in the last quarter. Finally, State of Wyoming bought a new stake in shares of BioLife Solutions during the 1st quarter valued at about $52,000. Institutional investors own 93.24% of the company’s stock.

BioLife Solutions Stock Performance

Shares of NASDAQ:BLFS opened at $28.49 on Friday. The firm has a market cap of $1.39 billion, a PE ratio of -356.08 and a beta of 1.94. The firm’s fifty day moving average is $24.44 and its 200-day moving average is $23.05. BioLife Solutions has a 52 week low of $17.86 and a 52 week high of $30.00.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. The business had revenue of $27.50 million during the quarter, compared to the consensus estimate of $25.66 million. BioLife Solutions had a positive return on equity of 1.81% and a negative net margin of 2.80%. Sell-side analysts forecast that BioLife Solutions will post 0.02 EPS for the current year.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.